EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
Krystal Biotech, Inc. (KRYS) had EBITDA Margin of 43.13% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$389.13M |
|
$204.83M |
|
$23.05M |
|
$366.08M |
|
$227.84M |
|
$161.29M |
|
$28.18M |
|
$189.47M |
|
$189.47M |
|
$204.83M |
|
$204.83M |
|
$204.83M |
|
$204.83M |
|
$161.29M |
|
$167.85M |
|
28.94M |
|
29.95M |
|
$7.08 |
|
$6.84 |
|
| Balance Sheet Financials | |
$1.02B |
|
$150.78M |
|
$309.19M |
|
$1.33B |
|
$102.94M |
|
-- |
|
$11.29M |
|
$114.23M |
|
$1.22B |
|
$1.22B |
|
$1.22B |
|
29.19M |
|
| Cash Flow Statement Financials | |
$200.87M |
|
$-58.42M |
|
$8.71M |
|
$344.87M |
|
$496.30M |
|
$151.44M |
|
$54.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.95 |
|
-- |
|
-- |
|
-- |
|
-- |
|
94.08% |
|
41.45% |
|
41.45% |
|
|
EBITDA Margin |
43.13% |
48.69% |
|
52.64% |
|
$189.35M |
|
-- |
|
-- |
|
-- |
|
0.29 |
|
0.57 |
|
3.05 |
|
119.52 |
|
16.80% |
|
16.80% |
|
15.36% |
|
16.80% |
|
$41.78 |
|
$6.32 |
|
$6.71 |
|